GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells

[1]  Tudor I. Oprea,et al.  In vivo Effects of a GPR 30 Antagonist , 2016 .

[2]  S. Andò,et al.  Selective GPER activation decreases proliferation and activates apoptosis in tumor Leydig cells , 2013, Cell Death and Disease.

[3]  Christine Weissenborn,et al.  GPER-1 acts as a tumor suppressor in ovarian cancer , 2013, Journal of Ovarian Research.

[4]  A. Roessner,et al.  GPER-1 Expression Decreases During Breast Cancer Tumorigenesis , 2013, Cancer investigation.

[5]  A. Belfiore,et al.  Insulin-like growth factor-I regulates GPER expression and function in cancer cells , 2013, Oncogene.

[6]  Shan-wei Wang,et al.  Regulation of HRG-β1-induced proliferation, migration and invasion of MCF-7 cells by upregulation of GPR30 expression. , 2012, Molecular medicine reports.

[7]  M. Oka,et al.  Optimizing high-resolution melting analysis for the detection of mutations of GPR30/GPER-1 in breast cancer. , 2012, Gene.

[8]  S. Schüler,et al.  Effects of a Combined Treatment With GPR30 Agonist G-1 and Herceptin on Growth and Gene Expression of Human Breast Cancer Cell Lines , 2012, Cancer investigation.

[9]  Zhi-xuan Fu,et al.  Heregulin-β1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway. , 2012, Biochemical and biophysical research communications.

[10]  X. Wan,et al.  The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells. , 2012, Biochemical and biophysical research communications.

[11]  Y. Bang,et al.  Epigenetic-Based Therapies in Cancer , 2011, Drugs.

[12]  John S. Davis,et al.  The putative G-protein coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian and breast cancer cells in a GPER-independent manner. , 2012, American journal of translational research.

[13]  A. Vivacqua,et al.  GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells , 2012, Breast Cancer Research and Treatment.

[14]  B. Zhu,et al.  Role of Cyclin B1/Cdc2 Up-Regulation in the Development of Mitotic Prometaphase Arrest in Human Breast Cancer Cells Treated with Nocodazole , 2011, PloS one.

[15]  A. Roessner,et al.  G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer , 2011, Breast Cancer Research and Treatment.

[16]  S. Das,et al.  GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERα) phosphorylation signals. , 2011, Endocrinology.

[17]  B. Olde,et al.  The GPER1 Agonist G-1 Attenuates Endothelial Cell Proliferation by Inhibiting DNA Synthesis and Accumulating Cells in the S and G2 Phases of the Cell Cycle , 2011, Journal of Vascular Research.

[18]  K. Sabapathy,et al.  An essential role for p73 in regulating mitotic cell death , 2010, Cell Death and Differentiation.

[19]  S. Ho,et al.  Activation of GPR30 inhibits growth of prostate cancer cells via sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G2 cell-cycle arrest , 2010, Cell Death and Differentiation.

[20]  Tudor I. Oprea,et al.  The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. , 2010, Cancer research.

[21]  R. Schneider-Stock,et al.  APC promoter hypermethylation is an early event in endometrial tumorigenesis , 2010, Cancer science.

[22]  C. Qualls,et al.  GPR 30 Predicts Poor Survival for Ovarian Cancer , 2010 .

[23]  N. Joste,et al.  GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer , 2010, Breast Cancer Research and Treatment.

[24]  A. Roessner,et al.  Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells , 2010, Breast Cancer Research and Treatment.

[25]  F. Jin,et al.  Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas. , 2009, Chinese medical journal.

[26]  N. Joste,et al.  GPR30 predicts poor survival for ovarian cancer. , 2009, Gynecologic oncology.

[27]  Tudor I. Oprea,et al.  In vivo Effects of a GPR30 Antagonist , 2009, Nature chemical biology.

[28]  Tinghe Yu,et al.  The Correlation between GPR30 and Clinicopathologic Variables in Breast Carcinomas , 2009, Technology in cancer research & treatment.

[29]  H. Volk,et al.  Human Chorionic Gonadotropin Attracts Regulatory T Cells into the Fetal-Maternal Interface during Early Human Pregnancy1 , 2009, The Journal of Immunology.

[30]  R. Schneider-Stock,et al.  P16 alterations increase the metastatic potential of endometrial carcinoma. , 2008, Gynecologic oncology.

[31]  S. Andò,et al.  Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. , 2008, Endocrinology.

[32]  E. Prossnitz,et al.  The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation. , 2008, Endocrinology.

[33]  Tudor I. Oprea,et al.  Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. , 2008, Annual review of physiology.

[34]  I. Poola,et al.  The Cell Surface Estrogen Receptor, G Protein- Coupled Receptor 30 (GPR30), is Markedly Down Regulated During Breast Tumorigenesis , 2008, Breast cancer : basic and clinical research.

[35]  King-Jen Chang,et al.  The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population. , 2007, Taiwanese journal of obstetrics & gynecology.

[36]  Meenakshi Singh,et al.  GPR30: a novel indicator of poor survival for endometrial carcinoma. , 2007, American journal of obstetrics and gynecology.

[37]  Tudor I. Oprea,et al.  G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. , 2007, Cancer research.

[38]  J. Gutkind,et al.  G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.

[39]  D. Giri,et al.  Distribution of GPR30, a Seven Membrane–Spanning Estrogen Receptor, in Primary Breast Cancer and its Association with Clinicopathologic Determinants of Tumor Progression , 2006, Clinical Cancer Research.

[40]  Tudor I. Oprea,et al.  Virtual and biomolecular screening converge on a selective agonist for GPR30 , 2006, Nature chemical biology.

[41]  S. Andò,et al.  The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. , 2006, Molecular endocrinology.

[42]  S. Andò,et al.  The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. , 2006, Molecular endocrinology.

[43]  Christopher J Kemp,et al.  Tumor suppressor genetics. , 2005, Carcinogenesis.

[44]  Eric R. Prossnitz,et al.  A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling , 2005, Science.

[45]  J. Dong,et al.  Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. , 2005, Endocrinology.

[46]  D. Tripathy,et al.  Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. , 2004, The oncologist.

[47]  S. Andò,et al.  The G Protein-coupled Receptor GPR30 Mediates c-fos Up-regulation by 17β-Estradiol and Phytoestrogens in Breast Cancer Cells* , 2004, Journal of Biological Chemistry.

[48]  H. Schaller,et al.  Sphingosine-1-phosphate is a high-affinity ligand for the G protein-coupled receptor GPR6 from mouse and induces intracellular Ca2+ release by activating the sphingosine-kinase pathway. , 2003, Biochemical and biophysical research communications.

[49]  T. Manninen,et al.  Progestin and G protein-coupled receptor 30 inhibit mitogen-activated protein kinase activity in MCF-7 breast cancer cells. , 2002, Endocrinology.

[50]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[51]  T. Manninen,et al.  G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. , 2002, Endocrinology.

[52]  Stefan Dimitrov,et al.  Histone H3 phosphorylation and cell division , 2001, Oncogene.

[53]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[54]  K. Bland,et al.  Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. , 2000, Molecular endocrinology.

[55]  P. Fisher,et al.  Cell cycle arrest. , 1995, Science.